Weissella Cibaria JW15 Consumption and NK Cell Activity
NCT ID: NCT03209635
Last Updated: 2017-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2016-04-01
2017-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Consumption of Dairy Yogurt Enhanced Immune Function
NCT02535663
Immune Benefits of Consumption of Dairy Yogurt in Elderly
NCT03051425
Evaluation of the Effects of Routine Intake of Fresh vs- Pasteurized Yoghurt on the Immune System in Healthy Adults
NCT06263686
The Effct of Chitooligosaccharide on Immune Function in Healthy Adults
NCT00468962
Immune System Stimulation by Probiotic Food Supplementation
NCT03049579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
Placebo
4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
Probiotic
4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
Probiotic
4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
Probiotic
4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with 4,000-8,000 leukocyte counts
Exclusion Criteria
* Taking medicine related to inflammation within one month before screening
* Allergy to probiotics
* Lactose intolerance
* Diabetes
* History/presence of significant metabolic disease
* Acute or chronic disease requiring treatment
* Taking any medications
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jong Ho Lee
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jong Ho Lee, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Dept. of Food and Nutrition, Colleage of Human Ecology, Yonsei University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI_probiotic_NK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.